Hussman Strategic Advisors Inc. bought a new stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,600 shares of the medical instruments supplier's stock, valued at approximately $1,955,000. Hussman Strategic Advisors Inc. owned about 0.05% of ICU Medical at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in ICUI. Allworth Financial LP grew its holdings in ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 100 shares in the last quarter. Venturi Wealth Management LLC grew its stake in shares of ICU Medical by 1,510.0% in the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier's stock valued at $59,000 after acquiring an additional 302 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in ICU Medical during the third quarter worth about $72,000. Greenleaf Trust acquired a new stake in ICU Medical in the 3rd quarter worth about $207,000. Finally, OLD National Bancorp IN bought a new stake in ICU Medical in the 3rd quarter valued at about $218,000. Institutional investors own 96.10% of the company's stock.
Insider Activity
In other ICU Medical news, COO Christian B. Voigtlander sold 1,430 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $158.00, for a total transaction of $225,940.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David C. Greenberg sold 972 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the transaction, the director now owns 5,037 shares in the company, valued at $796,400.07. This trade represents a 16.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 17,737 shares of company stock valued at $2,879,752 over the last quarter. 6.70% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Several brokerages have recently commented on ICUI. Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a report on Wednesday, November 13th. Jefferies Financial Group upgraded ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 price objective on the stock in a research note on Wednesday, December 11th. StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, November 20th. Finally, KeyCorp increased their target price on ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $199.67.
Check Out Our Latest Stock Report on ICU Medical
ICU Medical Price Performance
ICUI stock traded down $5.73 during trading on Friday, reaching $157.42. 159,367 shares of the company were exchanged, compared to its average volume of 190,778. ICU Medical, Inc. has a twelve month low of $93.36 and a twelve month high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The company has a market capitalization of $3.85 billion, a price-to-earnings ratio of -34.45 and a beta of 0.63. The company has a 50-day moving average of $160.74 and a two-hundred day moving average of $165.62.
About ICU Medical
(
Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Further Reading
Before you consider ICU Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.
While ICU Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
